Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2314-7253

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies ; volume:8 ; number:1 ; day:26 ; month:3 ; year:2022 ; pages:1-11 ; date:12.2022
Future Journal of Pharmaceutical Sciences ; 8, Heft 1 (26.3.2022), 1-11, 12.2022

Creator: Iheanacho, Chinonyerem O.
Eze, Uchenna I. H.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s43094-022-00409-5

URN: urn:nbn:de:101:1-2022061723233796607123

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Iheanacho, Chinonyerem O.
Eze, Uchenna I. H.
SpringerLink (Online service)

Other Objects (12)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Quelle

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Aufsatzsammlung

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Quelle

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Aufsatzsammlung

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Quelle

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Aufsatzsammlung

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

COVID-19

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

COVID-19

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

COVID-19 Impfpflichtgesetz : mit der COVID-19-Impfpflichtverordnung (COVID-19-IV)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

COVID-19

COVID-19

Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

Related objects

Reset password